BofA says “encouraging” phase 3 data presented by BridgeBio (BBIO) evaluating acoramidis in ATTR-CM has a “positive read through” for Intellia Therapeutics (NTLA), whose NTLA-2001 gene editing program is approaching a global pivotal study. The firm, which thinks the data from BridgeBio’s program supports further research in the space, notes that Intellia’s “innovative strategy” could lead to durable TTR reduction after a single dose. BofA keeps a Buy rating and $91 price target on Intellia shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics price target raised to $91 from $89 at BofA
- Intellia Therapeutics price target lowered to $107 from $111 at Chardan
- Intellia Rises on Promising Phase 1 Data in Hereditary Angioedema
- Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
- Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023